miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
// Man Gao 1 , Lingling Miao 1 , Mingxia Liu 1 , Chenggang Li 1 , Cunzhi Yu 1 , Hong Yan 1 , Yongxiang Yin 2 , Yizheng Wang 3 , Xinming Qi 1 , Jin Ren 1 1 Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, CAS., Shanghai, P.R. China 2 Department of Pathology, Wuxi Maternity and Children Health Hospital Affiliated Nanjing Medical University, Wuxi, China 3 The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing, China Correspondence to: Xinming Qi, email: xmqi@cdser.simm.ac.cn Jin Ren, email: jren@cdser.simm.ac.cn Keywords: breast cancer, MRP1, miRNA, chemoresistance, doxorubicin Received: August 11, 2015 Accepted: June 09, 2016 Published: July 26, 2016 ABSTRACT Multidrug resistance-associated protein 1 (MRP1) is an important efflux transporter and overexpression of MRP1 usually leads to chemoresistance in breast cancer. Here, we found MRP1 overexpressed in human breast cancer tissues and breast cancer cell lines (compared with normal breast tissues and cell line, respectively). And MRP1 level increased in doxorubicin resistant MCF-7 cells compared with parental MCF-7 cells. Increasing evidences suggest microRNAs (miRNAs) influence chemotherapy response. We found miR-145 level decreased in human breast cancer tissues, breast cancer cell lines and doxorubicin resistant MCF-7 cells, and inversely correlated with MRP1 expression level. In the process of constructing MCF-7 doxorubicin resistant cell line, escalating doxorubicin markedly decreased miR-145 level, following by increased MRP1 level. Further study showed, miR-145 suppressed MRP1 expression by directly targeting MRP1 3’-untranslated regions. Overexpression of miR-145 sensitized breast cancer cells to doxorubicin in vitro and enhanced to doxorubicin chemotherapy in vivo through inducing intracellular doxorubicin accumulation via inhibiting MRP1. Taken together, our study revealed miR-145 sensitizes breast cancer to doxorubicin by targeting MRP1 and indicated the potential application in developing MRP1 inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“A broad range of anti-cancer drugs are extruded by MRP1 [10, 11].”
Background
Cited by
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Gao, R., Fang, C., Xu, J., Tan, H., Li, P., & Ma, L. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.01.005 · Cited by 99
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Self-citation
Metadata
- Authors
- Gao, M., Miao, L., Liu, M., Li, C., Yu, C., Yan, H., Yin, Y., Wang, Y., Qi, X., & Ren, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-07-26
- Volume
- 7
- Issue
- 37
- Pages
- 59714-59726
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2507115513
- Cited by
- 96
- References
- 1
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. https://app.cochat.ai/papers/10.18632/oncotarget.10845
- The paper
- Gao, M., Miao, L., Liu, M., Li, C., Yu, C., Yan, H., Yin, Y., Wang, Y., Qi, X., & Ren, J. (2016). miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. https://doi.org/10.18632/oncotarget.10845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.